Journal article
Immunosuppressant Drugs and Bone Disease
Journal of clinical densitometry, v 1(4), pp 317-321
1998
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Immunosuppressant agents are used widely for a variety of diseases, and their usage will increase as organ transplantation becomes more frequent. One of the consequences of their administration is the occurrence of rapid bone loss with fractures. Generally, glucocorticoids (GC) are the main culprit, but calmodulin-calcineurin phosphatase inhibitors, e.g., cyclosporine and tacrolimus, seem to play a role as does the underlying disease, which necessitates treatment or organ transplantation. The mechanisms for the bone disease are multifactorial and actively being researched. The management at present is largely empirical and consists of calcium, vitamin D, and antiresorbers, especially bisphosphonates. In order to achieve an optimum treatment strategy, bone density measurements are essential to define the severity of the bone loss, help decide therapy and monitor progress of the patient.
Metrics
Details
- Title
- Immunosuppressant Drugs and Bone Disease
- Creators
- Sol Epstein - Allegheny University of the Health Sciences
- Publication Details
- Journal of clinical densitometry, v 1(4), pp 317-321
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Allegheny University of the Health Sciences (1996-1998)
- Web of Science ID
- WOS:000078383900001
- Scopus ID
- 2-s2.0-0039449807
- Other Identifier
- 991019167315804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Endocrinology & Metabolism